21.01.2025 14:51:27

Crown Laboratories, Revance Amend A&R Merger Agreement; Increases Offer Price To $3.65/shr

(RTTNews) - Crown Laboratories and Revance Therapeutics (RVNC) announced that, on January 17, 2025, they amended their previously announced Amended and Restated Merger Agreement. Revance's stockholders will receive $3.65 per share of common stock, par value $0.001 per share in cash, without interest and less any applicable tax withholding, representing $0.55 or 17% per share more than the prior offer price.

Crown will extend its existing tender offer for all of Revance's outstanding Shares until one minute past 11:59 p.m., Eastern Time, on February 4, 2025.

Analysen zu Revance Therapeutics Incmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Revance Therapeutics Inc 3,44 0,00% Revance Therapeutics Inc